Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492
Galapagos NV announced that it has started a Phase I Proof-of-Mechanism study for GLPG0492, a candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy.
This Proof-of-Mechanism study follows the positive outcome of the first-in-human trial conducted for GLPG0492, which showed good safety and a pharmacokinetic (PK) profile supporting once-daily oral dosing. The Proof-of-Mechanism study aims to assess GLPG0492's effect on muscle function in healthy volunteers.
"This is the third time this year we initiate a clinical study designed to give insight into the potential clinical benefits of a candidate drug," said Piet Wigerinck, SVP Development. "We aim to finalize this study by the end of 2011 before further evaluating the compound in a patient population."
Galapagos plans to conduct the placebo-controlled, multiple ascending dose study in at least 24 healthy volunteers using a once daily dosing regimen for two weeks. The study will include early measurements of muscle function. In addition to Proof-of-Mechanism investigation, the safety, tolerability and pharmacokinetics of GLPG0492 will be assessed further.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

A novel method to precisely deliver therapeutics inside the body - Ultrasound-controlled nanomaterials can provide on-demand, high precision delivery of proteins into human cells
Agilent Technologies Opens Global Manufacturing Facility for Life Sciences Instruments
GE Healthcare acquires bioprocessing start-up - Obtaining nanofiber-based platform purification technology for biopharmaceutical production

Analyze proteins and protein interactions with hitherto unseen performance - Life-science startup Actome announces release of first commercial products
Bayer CropScience accelerates expansion of biotech and seed business with investments of around EUR 3.5 billion through 2018

Falling Walls announces Science Breakthrough of the Year 2023 laureates - “These outstanding breakthroughs will change the face of the world and impressively prove what ingenuity, curiosity and courage can achieve”
